TRENDS

21 Drug Makers Expect 1.6% Increase in Sales but Decline in Profits in FY2017

November 15, 2017
By Reiji Anasako Twenty-one Japanese drug makers are likely to report an overall 1.6% increase in sales and 1.2% decline in operating profit for the fiscal year ending March 2018. Though global products have been doing well, the domestic market…

To read the full story

TRENDS

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…